Study to Evaluate the Safety and Tolerability of CC-94676 in Participants With Metastatic Castration-Resistant Prostate Cancer
Study Phase: Phase 1
Recruitment Status: Recruiting
Start Date: June 22, 2020
End Date: July 09, 2025
BMS Study Connect Contact Center www.BMSStudyConnect.com
855-907-3286
855-907-3286
First line of the email MUST contain the NCT# and Site #.
Inclusion Criteria:
- Must have histologically or cytologically confirmed adenocarcinoma of the prostate
- Progressed on androgen deprivation therapy (ADT) and at least one prior secondary hormonal therapy approved for castration-resistant prostate cancer (CRPC)
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1
Exclusion Criteria:
- Prior treatment with an androgen receptor (AR) degrader
- Concurrent malignancy (present during screening) requiring treatment or history of prior malignancy active within 1 year prior to the first dose of IP
- Clinically significant venous thromboembolism within 3 months prior to the first dose of IP
- Any significant medical condition, such as uncontrolled infection, laboratory abnormality, or psychiatric illness Other protocol-defined inclusion/exclusion criteria apply
-
Conditions:
- Prostatic Neoplasms
- Neoplasms